Report summarizes advances in cancer immunology and immunotherapy, highlighting AI's role in recognizing tumor antigens.
The 22nd Annual Meeting of the Association for Cancer Immunotherapy (CIMT) was held from May 12 to May 14, 2025, in Mainz, Germany. The event brought together 674 academic and clinical professionals from 27 countries across five continents. As a central forum for the global cancer immunotherapy community, the meeting facilitated in-depth discussions on the most recent advances in cancer immunology and immunotherapy. Dedicated sessions explored cutting-edge topics such as the interplay between the nervous and immune systems in cancer, as well as the application of artificial intelligence to decipher how antigen receptors recognize tumor antigens – insights that are shaping the development of next-generation immunotherapies. This report offers a summary of the most significant highlights and key takeaways from CIMT2025.
No takes yet. Share an insight, caveat, or question.
Dahl et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: